&lt;p&gt;The Emerging Roles of miR-125b in Cancers&lt;/p&gt;

Wang, Ying; Zeng, Guilin; Jiang, Yicheng

doi:10.2147/cmar.s232388

Cited by 75 publications

(50 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding the downregulated miRNAs, hsa-miR-125b-5p is recognized as the most common downregulated miRNA in several cancers [73]. Other identified miRNAs like hsa-miR-139-5p, hsa-miR-205-5p, hsa-miR-486-5p, and hsa-miR-99a-5p have shown strong involvement in neoplastic transformations and some studies are trying to use these miRNAs for the development of novel therapeutic strategies in BC [74][75][76][77].…”

Section: Discussionmentioning

confidence: 99%

Identification of Modulated MicroRNAs Associated with Breast Cancer, Diet, and Physical Activity

Falzone

Grimaldi

Celentano

et al. 2020

Cancers

View full text Add to dashboard Cite

Background: Several studies have shown that healthy lifestyles prevent the risk of breast cancer (BC) and are associated with better prognosis. It was hypothesized that lifestyle strategies induce microRNA (miRNA) modulation that, in turn, may lead to important epigenetic modifications. The identification of miRNAs associated with BC, diet, and physical activity may give further insights into the role played by lifestyle interventions and their efficacy for BC patients. To predict which miRNAs may be modulated by diet and physical activity in BC patients, the analyses of different miRNA expression datasets were performed. Methods: The GEO DataSets database was used to select miRNA expression datasets related to BC patients, dietary interventions, and physical exercise. Further bioinformatic approaches were used to establish the value of selected miRNAs in BC development and prognosis. Results: The analysis of datasets allowed the selection of modulated miRNAs associated with BC development, diet, and physical exercise. Seven miRNAs were also associated with the overall survival of BC patients. Conclusions: The identified miRNAs may play a role in the development of BC and may have a prognostic value in patients treated with integrative interventions including diet and physical activity. Validation of such modulated miRNAs on BC patients undergoing lifestyle strategies will be mandatory.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of Modulated MicroRNAs Associated with Breast Cancer, Diet, and Physical Activity

Falzone

Grimaldi

Celentano

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Thus, these miRNAs are abundantly expressed in normal liver [27] and seven of them (miR-122, let-7a, miR-22, -125b, -143, -194 and -24) are within the first 20 liver-specific miRNAs called "atlas liver" [30]. The expression levels of miR-122, let-7a, miR-22, -125b, -143, -194 and -199a have been described to be downregulated in liver cancer cells and function as tumor suppressor miRNAs, as these miRNAs are involved in inhibiting proliferation, cell cycle progression, epithelial-mesenchymal transition and activating apoptosis and autophagy [22,[31][32][33][34][35][36][37][38]. On the contrary, miR-21, -24, -210 and -224 have been reported to be upregulated in HCC and function as oncomiRs, promoting proliferation, cell cycle progression, biliary tumor growth, angiogenesis and aggressiveness [31,[39][40][41][42].…”

Section: Discussionmentioning

confidence: 99%

The Effect of Methylselenocysteine and Sodium Selenite Treatment on microRNA Expression in Liver Cancer Cell Lines

Lendvai

Szekerczés

Kontsek

et al. 2020

Pathol. Oncol. Res.

View full text Add to dashboard Cite

The unique character of selenium compounds, including sodium selenite and Se-methylselenocysteine (MSC), is that they exert cytotoxic effects on neoplastic cells, providing a great potential for treating cancer cells being highly resistant to cytostatic drugs. However, selenium treatment may affect microRNA (miRNA) expression as the pattern of circulating miRNAs changed in a placebo-controlled selenium supplement study. This necessitates exploring possible changes in the expression profiles of miRNAs. For this, miRNAs being critical for liver function were selected and their expression was measured in hepatocellular carcinoma (HLE and HLF) and cholangiocarcinoma cell lines (TFK-1 and HuH-28) using individual TaqMan MicroRNA Assays following selenite or MSC treatments. For establishing tolerable concentrations, IC 50 values were determined by performing SRB proliferation assays. The results revealed much lower IC 50 values for selenite (from 2.7 to 11.3 μM) compared to MSC (from 79.5 to 322.6 μM). The treatments resulted in cell line-dependent miRNA expression patterns, with all miRNAs found to show fold change differences; however, only a few of these changes were statistically different in treated cells compared to untreated cells below IC 50. Namely, miR-199a in HLF, miR-143 in TFK-1 upon MSC treatment, miR-210 in HLF and TFK-1, miR-22,-24,-122, −143 in HLF upon selenite treatment. Fold change differences revealed that miR-122 with both selenium compounds, miR-199a with MSC and miR-22 with selenite were affected. The miRNAs showing minimal alterations included miR-125b and miR-194. In conclusion, our results revealed moderately altered miRNA expression in the cell lines (less alterations following MSC treatment), being miR-122, −199a the most affected and miR-125b,-194 the least altered miRNAs upon selenium treatment.

show abstract

“…MiR-125b is a member of the miR-125 family, which is known to play a crucial role in many cancer-related processes including proliferation, cell differentiation and apoptosis (18). The targeting of multiple genes involved in the process of initiation and progression of cancer by miR-125b has been described in the literature and miR-125b dysregulation is commonly seen in many cancers.…”

Section: Discussionmentioning

confidence: 99%

“…The targeting of multiple genes involved in the process of initiation and progression of cancer by miR-125b has been described in the literature and miR-125b dysregulation is commonly seen in many cancers. Interestingly, miR-125b targets both tumour suppressor genes and oncogenes, leading to its up-or down-regulation having distinct effects, which seem to be dependent on specific tumour type (18). Down-regulation of miR-125b has been described in breast cancer, non-small-cell lung cancer, oesophageal squamous cell cancer, bladder cancer, thyroid cancer, melanoma, hepatocellular cancer, ovarian cancer, osteosarcoma, chondrosarcoma, and CRC.…”

Section: Discussionmentioning

confidence: 99%

“…Down-regulation of miR-125b has been described in breast cancer, non-small-cell lung cancer, oesophageal squamous cell cancer, bladder cancer, thyroid cancer, melanoma, hepatocellular cancer, ovarian cancer, osteosarcoma, chondrosarcoma, and CRC. Its up-regulation has been reported in retinoblastoma, nasopharyngeal cancer, glioblastoma and certain leukemias (18,19). Among others, miR-125b targets the p53 tumour suppressor gene: a key regulator of apoptosis (20).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association of miR-125b, miR-17 and let-7c Dysregulations With Response to Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With Metastatic Colorectal Cancer

Fiala¹,

Šorejs²,

Hošek³

et al. 2020

Cancer Genomics Proteomics

View full text Add to dashboard Cite

Background/Aim: MicroRNAs (miRs) play an important role in the regulation of cancer-related processes and are promising candidates for cancer biomarkers. The aim of the study was to evaluate the association of response to anti-EGFR monoclonal antibodies (mAbs) with selected miR expression profiles, including miR-125b, let-7c, miR-99a, miR-17, miR-143 and miR-145 in metastatic colorectal cancer (mCRC) patients. Patients and Methods: This retrospective study included 46 patients with mCRC harbouring wild-type RAS gene treated with cetuximab or panitumumab combined with chemotherapy in first-or second-line therapy. The miR expression was assessed using qRT-PCR. Results: Down-regulation of miR-125b and let-7c and up-regulation of miR-17 were found in the tumour tissue (p=0.0226, p=0.0040, p<0.0001). Objective response rate (ORR) was associated with up-regulation of miR-125b (p=0.0005). Disease control rate (DCR) was associated with up-regulation of miR-125b and let-7c (p=0.0383 and p=0.0255) and down-regulation of miR-17 (p=0.0464). MiR-125b showed correlation with progression-free and overall survival (p=0.055 and p=0.006). Conclusion: The results show that up-regulation of miR-125b is associated with higher ORR and DCR and longer survival; let-7c up-regulation and miR-17 downregulation are associated with higher DCR in mCRC patients treated with anti-EGFR mAbs. Colorectal cancer (CRC) is one of the most common malignancies whose incidence has been increasing in developed countries (1). Clinical trials have provided evidence for the efficacy and safety of monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR) represented by cetuximab and panitumumab, in the treatment of patients with metastatic CRC (mCRC). Both agents have been widely used in mCRC patients with tumours harbouring a wild-type RAS gene. Despite the standard use of RAS gene mutations as effective biomarkers predictive of resistance to anti-EGFR mAbs, there is a large proportion of patients with tumours harbouring a wild-type RAS gene who obtain poor benefit from this systemic treatment (2-9). There is therefore an urgent need for novel complementary predictive and prognostic biomarkers. MicroRNAs (miRs) are small non-coding RNAs, consisting of approximately 18-25 nucleotides that play an important role in the regulation of target gene expression. MiRs are involved in the regulation of key cancer-related processes including proliferation, differentiation, apoptosis, cell adhesion and angiogenesis (10). The role of miRs as biomarkers useful in diagnostics or prognostic estimation in cancer patients has been extensively studied.

show abstract

<p>The Emerging Roles of miR-125b in Cancers</p>

Cited by 75 publications

References 101 publications

Identification of Modulated MicroRNAs Associated with Breast Cancer, Diet, and Physical Activity

Identification of Modulated MicroRNAs Associated with Breast Cancer, Diet, and Physical Activity

The Effect of Methylselenocysteine and Sodium Selenite Treatment on microRNA Expression in Liver Cancer Cell Lines

Association of miR-125b, miR-17 and let-7c Dysregulations With Response to Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With Metastatic Colorectal Cancer

Contact Info

Product

Resources

About